Journal of internal medicine

The most recent articles from: J. Intern. Med. February 2024

J. Intern. Med. · Feb 2024

Multicenter Study

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.

Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and FLT3-internal tandem duplication (FLT3-ITD) respond infrequently to salvage chemotherapy. ⋯ The sorafenib plus VAH regimen was well tolerated and highly active against R/R AML with FLT3-ITD. This regimen may be a suitable therapeutic option for this population, but larger population trials are needed to be explored.

read more… or not…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.